LeonaBio (LONA) Change in Accured Expenses (2019 - 2026)
LeonaBio (LONA) reported Change in Accured Expenses of -$3.4 million for Q1 2026, up 56.08% year-over-year from -$2.2 million in Q1 2025, and up 69.31% on a QoQ basis from -$11.0 million in Q4 2025.
LeonaBio (LONA) has 8 years of Change in Accured Expenses data on file, last reported at -$3.4 million in Q1 2026.
- Quarterly Change in Accured Expenses rose 56.08% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.0 million (down 67.94% YoY) and the FY2025 annual result came in at -$21.3 million, down 271.1% from the prior year.
- Change in Accured Expenses grew to -$3.4 million in Q1 2026 per LONA's latest filing, from -$11.0 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $6.9 million in Q3 2023 and bottomed at -$11.0 million in Q4 2025.
- The 5-year median for Change in Accured Expenses is $164000.0 (2022), against an average of -$1.2 million.
- The widest annual swing landed in 2023, when Change in Accured Expenses soared 1100.17%; it then tumbled 2325.0% in 2024.
- Tracing LONA's Change in Accured Expenses over 5 years: stood at $1.2 million in 2022, then slumped by 82.02% to $208000.0 in 2023, then plunged by 2325.0% to -$4.6 million in 2024, then sank by 136.73% to -$11.0 million in 2025, then jumped by 69.31% to -$3.4 million in 2026.
- Per Business Quant, the three latest LONA Change in Accured Expenses figures stand at -$3.4 million (Q1 2026), -$11.0 million (Q4 2025), and -$207000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -176.03 Mn |
| 10 | LeonaBio | 181.52 Mn | 113.84 Mn | - | -3.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.36 Mn |
| Mar 31, 2026 | -3.36 Mn |
| Dec 31, 2025 | -10.96 Mn |
| Dec 31, 2025 | -10.96 Mn |
| Sep 30, 2025 | -207,000.00 |
| Sep 30, 2025 | -207,000.00 |
| Jun 30, 2025 | -2.52 Mn |
| Jun 30, 2025 | -2.52 Mn |
| Mar 31, 2025 | -7.66 Mn |
| Mar 31, 2025 | -7.66 Mn |
| Dec 31, 2024 | -4.63 Mn |
| Dec 31, 2024 | -4.63 Mn |
| Sep 30, 2024 | 838,000.00 |
| Sep 30, 2024 | 838,000.00 |
| Jun 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Mar 31, 2024 | -3.25 Mn |
| Mar 31, 2024 | -3.25 Mn |
| Dec 31, 2023 | 208,000.00 |
| Dec 31, 2023 | 208,000.00 |
| Sep 30, 2023 | 6.95 Mn |
| Sep 30, 2023 | 6.95 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Mar 31, 2023 | -1.29 Mn |
| Mar 31, 2023 | -1.29 Mn |
| Dec 31, 2022 | 1.16 Mn |
| Dec 31, 2022 | 1.16 Mn |
| Sep 30, 2022 | 579,000.00 |
| Sep 30, 2022 | 579,000.00 |
| Jun 30, 2022 | 201,000.00 |
| Jun 30, 2022 | 201,000.00 |
| Mar 31, 2022 | 164,000.00 |
| Mar 31, 2022 | 164,000.00 |
| Dec 31, 2021 | 237,000.00 |
| Dec 31, 2021 | 237,000.00 |
| Sep 30, 2021 | 1.60 Mn |
| Sep 30, 2021 | 1.60 Mn |
| Jun 30, 2021 | 3.69 Mn |
| Jun 30, 2021 | 3.69 Mn |
| Mar 31, 2021 | -374,000.00 |
| Mar 31, 2021 | -374,000.00 |
| Dec 31, 2020 | -403,000.00 |
| Dec 31, 2020 | -403,000.00 |
| Sep 30, 2020 | 2.46 Mn |
| Sep 30, 2020 | 2.46 Mn |
| Jun 30, 2020 | 483,000.00 |
| Jun 30, 2020 | 483,000.00 |
| Mar 31, 2020 | 63,000.00 |
| Mar 31, 2020 | 63,000.00 |
| Dec 31, 2019 | -226,000.00 |
| Dec 31, 2019 | -226,000.00 |